Cost-Savings In Effective Clinical Reminders For HIV Testing

Published May 29, 2014
Boston, MA, USA - About 1.1 million individuals are living with HIV in the United States and it is estimated that approximately 15-20% are currently unaware of their status. To increase HIV testing rate, the Veterans Health Administration (VHA), the single largest health care system in the United States, has removed the requirement for formal pretest and posttest counseling and has substituted verbal consent for written informed consent prior to HIV testing.  In addition, many sites have installed clinical reminders to promote routine-based testing. Dr. Kee Chan, PhD, Assistant Professor of Health Science at Boston University and investigator at the Center for Healthcare Organization and Implementation Research at the Veterans Affairs Medical Centers in Boston and Bedford, led a group of researchers to conduct a comparative cost analysis for three alternative strategies for HIV testing:  1) physician-based traditional HIV testing and counseling in the absence of clinical reminders; 2) clinical reminders and nurse-based stream-lined counseling with telephone notifications for negative results; and 3) clinical reminders without pre-test counseling and with telephone notifications for negative results Dr. Chan highlights, "My Boston research group collaborated with VA Greater Los Angeles to evaluate the annual total costs and costs per new case. The cost of a clinical reminder system with pre-test counseling was $81,726 compared to $109,208 for traditional HIV testing in one year.  A clinical reminder system without counseling had the most cost-savings per case identified of $57.69, compared to traditional testing at $120.93. The findings support the current implementation of the clinical reminder system to promote HIV testing in the VA." This study, "Comparative Cost Analysis of Clinical Reminder for HIV Testing at the Veterans Affairs Healthcare System," is published inValue in Health.

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Related Stories

Rethinking Medication Adherence: A Stakeholder Blueprint

May 12, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a report from its Medication Adherence and Persistence Special Interest Group that provides valuable insights into the perspectives of key stakeholders on interventions to improve medication adherence. The report, “Stakeholders’ Perspectives on Medication Adherence Enhancing Interventions: An ISPOR Report,” was published in the May 2025 issue of Value in Health.

New Research Reveals Surprising Trends in Women's Health Economics Authorship

May 12, 2025

Value in Health, the official journal of ISPOR announced the publication of new research analyzing women's representation in authorship of papers submitted to and published in Value in Health. The report, “How Well Are Women Represented in Authorship in HEOR? An Analysis of Value in Health: An ISPOR Report,” was published in the May 2025 issue of Value in Health.

Redefining Value in Care for Alzheimer's Disease and Dementia

Apr 8, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the publication of a special themed section of research papers that provide crucial insights into the complex health economics of Alzheimer's disease and related dementias (ADRD), offering a roadmap for future research and policy as the aging population grows and novel treatments emerge.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×